摘要
目的:研究复方苦参注射液联合顺铂腹腔灌注治疗恶性腹水的临床效果。方法:将42例恶性腹水患者随机分为治疗组和对照组,治疗组22例应用复方苦参注射液加顺铂腹腔灌注,对照组20例单纯应用顺铂治疗,观察治疗前后腹水的变化和不良反应。结果:治疗组控制腹水的控制率(CR+SD)为90.9%,对照组为65.0%,两组相比差异有显著性(P<0.05)。治疗组不良反应(腹痛、胃肠道反应及骨髓抑制)较对照组明显减轻,两组比较有显著性差异(P<0.05)。结论:复方苦参注射液联合顺铂腹腔灌注能有效地控制恶性腹水,疗效肯定且不良反应小。
Objective： To study the therapeutic efficacy of intraperitoneal perfusion of Compound Matrine injection and Cisplatin on malignant ascites. Methods： Forty - two patients of malignant ascites were randomly divided into treatment group and control group. 22 patients were treated with Compound Matrine injection and Cisplatin intraperitoneal perfusion （ treatment group） , and 20 patients were treated with Cisplatin intraperitoneal perfusion only （ control group）. The changes in volume of ascites and treatment side effects were observed. Results：The objective response rate（ CR and PR） of treatment group and control group were 90.9% and 65.0% respectively,and the difference was significant（ P 〈0.05 ）. The treatment group had a slighter side effect on abdominal pain, gastrointestinal rection and bone marrow depression, and the difference was significant（ P 〈 0.05 ）. Conclusion：The results suggest that intraperitoneal perfusion of Compound Matrine injection and Cisplatin is safe and effective in treating malignant ascites.
出处
《现代肿瘤医学》
CAS
2015年第10期1438-1440,共3页
Journal of Modern Oncology
关键词
恶性腹水
复方苦参注射液
顺铂
腹腔灌注化疗
malignant ascites
Compound Matrine injection
Cisplatin
intraperitoneal perfusion chemotherapy
